265 related articles for article (PubMed ID: 30474878)
1. Dramatic effect of nivolumab against melanoma and immune-related liver toxicity: A detailed histopathological and immunohistochemical analysis of nivolumab-induced liver toxicity.
Namiki T; Nojima K; Chikazawa S; Iwamoto Y; Otsuki Y; Albusani H; Miura K; Kiyokawa Y; Asakage T; Yokozeki H
J Dermatol; 2019 May; 46(5):e182-e183. PubMed ID: 30474878
[No Abstract] [Full Text] [Related]
2. Case of acute-onset type 1 diabetes induced by long-term immunotherapy with nivolumab in a patient with mucosal melanoma.
Maekawa T; Okada K; Okada H; Kado S; Kamiya K; Komine M; Murata S; Oka K; Ishibashi S; Ohtsuki M
J Dermatol; 2019 Dec; 46(12):e463-e464. PubMed ID: 31436330
[No Abstract] [Full Text] [Related]
3. Managing immune checkpoint-inhibitor-induced severe autoimmune-like hepatitis by liver-directed topical steroids.
Ziemer M; Koukoulioti E; Beyer S; Simon JC; Berg T
J Hepatol; 2017 Mar; 66(3):657-659. PubMed ID: 27908801
[No Abstract] [Full Text] [Related]
4. Hepatic Injury Induced by a Single Dose of Nivolumab - a Case Report and Literature Review.
Kopecký J; Kubecek O; Geryk T; Podhola M; Ziaran M; Priester P; Hanisova M; Borilova S
Klin Onkol; 2019; 32(2):133-138. PubMed ID: 30995854
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and toxicity of ipilimumab used after nivolumab in patients with melanoma.
Sato M; Uhara H; Koga H; Okuyama R
J Dermatol; 2018 Oct; 45(10):e287-e289. PubMed ID: 29655228
[No Abstract] [Full Text] [Related]
6. Nasal mucosal melanoma as a cause of epistaxis.
Behranwala R; Loku Waduge BH; Teo B
BMJ Case Rep; 2019 Jul; 12(7):. PubMed ID: 31302615
[TBL] [Abstract][Full Text] [Related]
7. Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient.
Teramoto Y; Nakamura Y; Asami Y; Imamura T; Takahira S; Nemoto M; Sakai G; Shimada A; Noda M; Yamamoto A
J Dermatol; 2017 May; 44(5):605-606. PubMed ID: 27334247
[No Abstract] [Full Text] [Related]
8. Rapidly Evolving Extensive Fluorodeoxyglucose-Positive Soft-Tissue Activity During Nivolumab Therapy.
Mangana J; Buset CS; Dummer R
JAMA Oncol; 2019 May; 5(5):730-731. PubMed ID: 30676614
[No Abstract] [Full Text] [Related]
9. Angioedema late in the course of adjuvant nivolumab therapy for melanoma.
Ratra A; Dasanu CA
J Oncol Pharm Pract; 2020 Jun; 26(4):1019-1021. PubMed ID: 31635547
[TBL] [Abstract][Full Text] [Related]
10. Type 1 diabetes in a melanoma patient treated with ipilimumab after nivolumab.
Omodaka T; Kiniwa Y; Sato Y; Suwa M; Sato M; Yamaguchi T; Sato A; Miyake T; Okuyama R
J Dermatol; 2018 Oct; 45(10):e289-e290. PubMed ID: 29667767
[No Abstract] [Full Text] [Related]
11. Immune checkpoint inhibitor-induced lymphocytic fasciitis.
Rischin A; Brady B; McLean C; Ostor AJK
Intern Med J; 2018 Dec; 48(12):1550-1552. PubMed ID: 30517989
[No Abstract] [Full Text] [Related]
12. Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
Ansorge C; Seufert J; Meiss F; von Bubnoff D
J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30411844
[No Abstract] [Full Text] [Related]
13. Nivolumab Induces Sustained Liver Injury in a Patient with Malignant Melanoma.
Matsubara T; Nishida T; Higaki Y; Tomita R; Shimakoshi H; Shimoda A; Osugi N; Sugimoto A; Takahashi K; Nakamatsu D; Mukai K; Yamamoto M; Fukui K; Adachi S; Inada M
Intern Med; 2018 Jun; 57(12):1789-1792. PubMed ID: 29434164
[TBL] [Abstract][Full Text] [Related]
14. Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study.
Long GV; Atkinson V; Lo S; Sandhu S; Guminski AD; Brown MP; Wilmott JS; Edwards J; Gonzalez M; Scolyer RA; Menzies AM; McArthur GA
Lancet Oncol; 2018 May; 19(5):672-681. PubMed ID: 29602646
[TBL] [Abstract][Full Text] [Related]
15. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
[No Abstract] [Full Text] [Related]
16. Nivolumab-induced colitis in a patient with malignant melanoma: A case report and immunological analysis.
Miyashita A; Fukushima S; Tsukamoto H; Itai H; Miyamoto H; Nakahara S; Kubo Y; Kimura T; Kuriyama H; Ihn H
J Dermatol; 2019 Sep; 46(9):e339-e341. PubMed ID: 30908699
[No Abstract] [Full Text] [Related]
17. Donor-derived cell-free DNA detects kidney transplant rejection during nivolumab treatment.
Hurkmans DP; Verhoeven JGHP; de Leur K; Boer K; Joosse A; Baan CC; von der Thüsen JH; van Schaik RHN; Mathijssen RHJ; van der Veldt AAM; Hesselink DA
J Immunother Cancer; 2019 Jul; 7(1):182. PubMed ID: 31300068
[TBL] [Abstract][Full Text] [Related]
18. Scleroderma-like syndrome associated with nivolumab treatment in malignant melanoma.
Cho M; Nonomura Y; Kaku Y; Nakabo S; Endo Y; Otsuka A; Kabashima K
J Dermatol; 2019 Jan; 46(1):e43-e44. PubMed ID: 29863795
[No Abstract] [Full Text] [Related]
19. Multiple nivolumab-induced CNS demyelination with spontaneous resolution in an asymptomatic metastatic melanoma patient.
Pillonel V; Dunet V; Hottinger AF; Berthod G; Schiappacasse L; Peters S; Michielin O; Aedo-Lopez V
J Immunother Cancer; 2019 Dec; 7(1):336. PubMed ID: 31791418
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab-Associated Colitis Mimicking Ulcerative Colitis.
Kubo K; Kato M; Mabe K
Clin Gastroenterol Hepatol; 2017 Sep; 15(9):A35-A36. PubMed ID: 28351793
[No Abstract] [Full Text] [Related]
[Next] [New Search]
